BRWA
VVOS icon

B. Riley Wealth Advisors’s Vivos Therapeutics VVOS Stock Holding History

B. Riley Wealth Advisors’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8K Hold
38,066
– – ﹤0.01% 899
2026
Q1 		$41.5K Sell
38,066
-5,465
-13% -$8.76K ﹤0.01% 838
2025
Q4 		$88.4K Hold
43,531
– – ﹤0.01% 942
2025
Q3 		$135K Sell
43,531
-26,000
-37% -$118K 0.01% 936
2025
Q2 		$220K Buy
+69,531
New +$176K 0.01% 849
2022
Q3 		– Sell
-4,032
Closed -$131K – 1537
2022
Q2 		$131K Buy
4,032
+89
+2% +$3.7K 0.01% 1099
2022
Q1 		$265K Buy
3,943
+772
+24% +$50.5K 0.01% 1071
2021
Q4 		$179K Buy
3,171
+1,132
+56% +$91.1K 0.01% 1289
2021
Q3 		$206K Buy
2,039
+650
+47% +$68.3K 0.01% 1236
2021
Q2 		$172K Buy
1,389
+250
+22% +$40.7K 0.01% 1246
2021
Q1 		$190K Buy
+1,139
New +$203K 0.01% 1207

Other funds holding VVOS

CWM
Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
KA
Kozak & Associates Highlands Ranch, Colorado $576M AUM 23.37% 1-Year Est. Return

B. Riley Wealth Advisors's VVOS Position: Q2 2026 in Review

B. Riley Wealth Advisors held its Vivos Therapeutics (VVOS) position steady in Q2 2026 at 38,066 shares worth $18.8K. The position accounts for ﹤0.01% of the portfolio, ranked #899.

B. Riley Wealth Advisors first reported a position in VVOS in Q1 2021 and has held it in 11 quarters since. The position peaked at $265K in Q1 2022. 4 funds tracked by Wall St. Rank hold VVOS as of Q2 2026.

  • B. Riley Wealth Advisors held 38,066 shares of Vivos Therapeutics worth $18.8K as of Q2 2026.
  • B. Riley Wealth Advisors left its Vivos Therapeutics share count unchanged in Q2 2026.
  • Vivos Therapeutics made up ﹤0.01% of B. Riley Wealth Advisors's portfolio in Q2 2026, its #899 holding.
  • B. Riley Wealth Advisors first reported a position in Vivos Therapeutics in Q1 2021 and has held it in 11 quarters since.
  • B. Riley Wealth Advisors's Vivos Therapeutics position peaked at $265K in Q1 2022.
  • 4 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2026.

Based on B. Riley Wealth Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.